2019
Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
Thompson J, Sridhar A, Tan W, Freeman A, Haider A, Allen C, Moore C, Orczyk C, Mazzon G, Khetrapal P, Shaw G, Rajan P, Mohammed A, Briggs T, Nathan S, Kelly J, Sooriakumaran P. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. Journal Of Urology 2019, 201: 1134-1143. PMID: 30730409, DOI: 10.1097/ju.0000000000000135.Peer-Reviewed Original ResearchConceptsSalvage robot-assisted radical prostatectomyRobot-assisted radical prostatectomyPositive surgical marginsSalvage prostatectomyRadical prostatectomySensitivity of magnetic resonance imagingField recurrenceMagnetic resonance imagingInfield recurrenceSurgical marginsHigher risk of positive surgical marginsGleason 3+3 diseasePrimary robotic assisted radical prostatectomyRisk of positive surgical marginsMagnetic resonance imaging concordancePositive surgical margin ratePartial ablationSalvage radical prostatectomyMagnetic resonance imaging sensitivityResonance imagingSurgical margin rateRisk of recurrenceCharacteristics of recurrenceProstatectomy histopathologyHigh-intensity focused ultrasound
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyIntravesical device-assisted therapies for non-muscle-invasive bladder cancer
Tan W, Kelly J. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology 2018, 15: 667-685. PMID: 30254383, DOI: 10.1038/s41585-018-0092-z.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerElectromotive drug administrationDevice-assisted therapiesBladder cancerHyperthermic chemotherapyDevice-assisted treatmentsIntravesical adjuvant treatmentHigh-risk diseaseResults of randomized trialsRisk of recurrenceRisk of progressionAlternative to BCGEffective treatment optionSingle-arm study designBladder cancer diagnosisBCG failureRandomized controlled trialsMaintenance regimensAdjuvant treatmentPatient cohortTreatment optionsRandomized trialsDrug AdministrationControlled trialsClinical guidelines